Corcept Therapeutics - Latest News and Information
CORT
Corcept Therapeutics advances cortisol modulation therapies focused on treating serious diseases by targeting the glucocorticoid receptor. The company conducts research and clinical development across endocrinology, oncology, metabolism, and neurology, aiming to unlock the therapeutic potential of cortisol modulation. Based in the United States, it communicates a commitment to scientific innovation and patient health through its pipeline and scientific publications.
Corcept's Drug Extends Patients' Lives in Key Ovarian Cancer Study
Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop
Securities Lawsuits Target Corcept and Aldeyra, Sparking Investor Scrutiny
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
FDA Says It Explained Issues Early on for Corcept's Rejected Cushing's Syndrome Drug
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Hypercortisolism Common in Patients with Resistant Hypertension
No recent deals for this company.
